{
    "id": "dbpedia_472_3",
    "rank": 78,
    "data": {
        "url": "https://www.emcdda.europa.eu/document-library/prevalence-use-and-acute-toxicity-associated-use-nbome-drugs_en",
        "read_more_link": "",
        "language": "en",
        "title": "Prevalence of use and acute toxicity associated with the use of NBOMe drugs",
        "top_image": "https://www.emcdda.europa.eu/themes/custom/euda/favicon.ico",
        "meta_img": "https://www.emcdda.europa.eu/themes/custom/euda/favicon.ico",
        "images": [
            "https://www.emcdda.europa.eu/themes/custom/euda/logo.svg",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/data_0.png.webp?itok=Xk4E6klU",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/countries.png.webp?itok=vMXvWq96",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/topics.png.webp?itok=6Yrs_Ial",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/best-practice.png.webp?itok=R5ja87TP",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/activities.png.webp?itok=tCsUbdtl",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/publications.png.webp?itok=1P2aENI0",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/events.png.webp?itok=vxC7b3FB",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/news.png.webp?itok=jrjeLfM2",
            "https://www.euda.europa.eu/sites/default/files/styles/scale_crop_500x281_2x_used_in_jumbotron_/public/images/2024-07/about_1.png.webp?itok=jjklGW1l",
            "https://www.euda.europa.eu/sites/default/files/images/2024-07/euda-logo-horizontal-white.svg",
            "https://www.euda.europa.eu/sites/default/files/images/2022-12/eu_logo1.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "There is evidence suggesting limited use of the NBOMe class of drugs as novel psychoactive substances compared with that of classical recreational drugs and other novel psychoactive substances such as mephedrone.",
        "meta_lang": "en",
        "meta_favicon": "/themes/custom/euda/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.euda.europa.eu/document-library/prevalence-use-and-acute-toxicity-associated-use-nbome-drugs_en",
        "text": "Data\n\nExplore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.\n\nData\n\nCountries\n\nWe work closely with the 27 EU Member States plus Norway and TÃ¼rkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.\n\nCountries\n\nBest practice\n\nThe content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses.\n\nBest practice\n\nActivities\n\nWe have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.\n\nActivities\n\nPublications\n\nExplore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it.\n\nAll publications"
    }
}